Gut microbiome encoded purine and amino acid pathways present prospective biomarkers for predicting metformin therapy efficacy in newly diagnosed T2D patients DOI Creative Commons
Ilze Elbere, Zigmunds Orlovskis, Laura Ansone

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: June 13, 2024

Metformin is widely used for treating type 2 diabetes mellitus (T2D). However, the efficacy of metformin monotherapy highly variable within human population. Understanding potential indirect or synergistic effects on gut microbiota composition and encoded functions could potentially offer new insights into predicting treatment designing more personalized treatments in future. We combined targeted metabolomics metagenomic profiling microbiomes newly diagnosed T2D patients before after therapy to identify pre-treatment biomarkers functional signatures induced changes responders. Our sequencing data were largely corroborated by our metabolic identified that enrichment microbial encoding purine degradation glutamate biosynthesis was associated with good response. Furthermore, we glutamine-associated amino acid (arginine, ornithine, putrescine) metabolism characterize differences therapy. Moreover, Responders' displayed a shifted balance between bacterial lipidA synthesis as well alterations glutamate-dependent N-acetyl-galactosamine its derivatives (e.g. CMP-pseudaminate) which suggest modulation cell walls barrier, thus mediating microbiome composition. Together, glutamine products may condition activity via multiple therefore serve important efficacy.

Language: Английский

Microbiome-based dietary supplements for better development and healthy brain DOI
Riddhi Upadhyay, Sugumar Mani, Murugan Sevanan

et al.

International review of neurobiology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Recent developments in managing luminal microbial ecology in patients with inflammatory bowel disease: from evidence to microbiome-based diagnostic and personalized therapy DOI

Erica Bonazzi,

Caterina De Barba,

G. Lorenzon

et al.

Expert Review of Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: April 17, 2025

Inflammatory bowel disease (IBD), including Crohn's and ulcerative colitis, is a chronic condition characterized by abnormal immune responses intestinal inflammation. Emerging evidence highlights the vital role of gut microbiota in IBD's onset progression. Recent advances have shaped diagnostic therapeutic strategies, increasingly focusing on microbiome-based personalized care. Methodology: this review covers studies from 2004 to 2024, reflecting surge research luminal microbial ecology IBD. Human were prioritized, with select animal included for mechanistic insights. Only English-language, peer-reviewed articles - clinical trials, systematic reviews, meta-analyses considered. Studies without validation excluded unless offering essential Searches conducted using PubMed, Scopus, Web Science. we explore mechanisms managing IBD-related microbiota, markers diagnosis novel therapies such as fecal transplantation, metabolite-based treatments, precision microbiome modulation. Additionally, technologies tools used analyze composition function settings. data supporting strategies based individual profiles are discussed. Standardized integration into practice will enhance IBD care, signaling shift toward microbiota-based medicine.

Language: Английский

Citations

0
Unlocking the Secrets of the Hair Microbiome: From Scalp Health to Therapeutic Advances DOI Creative Commons

Jibon Kumar Paul,

Mahir Azmal,

Omar Faruk Talukder

et al.

The Microbe, Journal Year: 2025, Volume and Issue: unknown, P. 100353 - 100353

Published: April 1, 2025

Language: Английский

Citations

0
Discovery of Lactomodulin, a Unique Microbiome-Derived Peptide That Exhibits Dual Anti-Inflammatory and Antimicrobial Activity against Multidrug-Resistant Pathogens DOI Open Access
Walaa K. Mousa, Rose Ghemrawi, Tareq Abu‐Izneid

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(8), P. 6901 - 6901

Published: April 7, 2023

The human body is a superorganism that harbors trillions of microbes, most which inhabit the gut. To colonize our bodies, these microbes have evolved strategies to regulate immune system and maintain intestinal homeostasis by secreting chemical mediators. There much interest in deciphering chemicals furthering their development as novel therapeutics. In this work, we present combined experimental computational approach identifying functional immunomodulatory molecules from gut microbiome. Based on approach, report discovery lactomodulin, unique peptide Lactobacillus rhamnosus exhibits dual anti-inflammatory antibiotic activities minimal cytotoxicity cell lines. Lactomodulin reduces several secreted proinflammatory cytokines, including IL-8, IL-6, IL-1β, TNF-α. As an antibiotic, lactomodulin effective against range pathogens, potent antibiotic-resistant strains such methicillin-resistant Staphylococcus aureus (MRSA) vancomycin-resistant Enterococcus faecium (VRE). multifunctional activity affirms microbiome encodes with promising therapeutic potential.

Language: Английский

Citations

10
Gut microbiome encoded purine and amino acid pathways present prospective biomarkers for predicting metformin therapy efficacy in newly diagnosed T2D patients DOI Creative Commons
Ilze Elbere, Zigmunds Orlovskis, Laura Ansone

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: June 13, 2024

Metformin is widely used for treating type 2 diabetes mellitus (T2D). However, the efficacy of metformin monotherapy highly variable within human population. Understanding potential indirect or synergistic effects on gut microbiota composition and encoded functions could potentially offer new insights into predicting treatment designing more personalized treatments in future. We combined targeted metabolomics metagenomic profiling microbiomes newly diagnosed T2D patients before after therapy to identify pre-treatment biomarkers functional signatures induced changes responders. Our sequencing data were largely corroborated by our metabolic identified that enrichment microbial encoding purine degradation glutamate biosynthesis was associated with good response. Furthermore, we glutamine-associated amino acid (arginine, ornithine, putrescine) metabolism characterize differences therapy. Moreover, Responders' displayed a shifted balance between bacterial lipidA synthesis as well alterations glutamate-dependent N-acetyl-galactosamine its derivatives (e.g. CMP-pseudaminate) which suggest modulation cell walls barrier, thus mediating microbiome composition. Together, glutamine products may condition activity via multiple therefore serve important efficacy.

Language: Английский

Citations

3